中国北京和日本长野，2020年11月30日-北京百奥赛图基因生物技术有限公司（以下简称"百奥赛图"）今日宣布，已与日本Ina Research Co., Ltd.（以下简称"INA"）签订商业代理协议，以拓展百奥赛图在日本市场的业务。
INA董事长和CEO Kenshi Nakagawa先生表示：“近年来我们感受到日本市场对于优质动物模型和临床前动物体内药效评价服务不断增长的需求，尤其是在免疫治疗领域。百奥赛图的模型和服务能力已被美国、欧洲和中国的许多客户和合作伙伴包括多家跨国药企所认可。我们很高兴能够和百奥赛图一起将这些先进的模型和高质量的服务介绍给日本企业和机构，加速新药创新。”
Ina Research 成立于 1974 年，总部位于日本长野县的伊纳市，在东京设有办事处。该公司的股票在JASDAQ交易所公开交易。Ina 主要为制药行业的客户进行分析和安全性和有效性研究，客户也包括生产农业化学品和医疗设备的公司。Ina的服务及研究领域包括药物依赖研究、中枢神经系统疗法的疗效研究、癌症研究、生殖和发育毒性研究以及动物模型。Ina与学术机构合作，在园区建立了一个研究中心，用以开展由日本医学研究开发机构资助的 CAR-T治疗的非临床安全研究。
Biocytogen Teams With Ina Research To Boost Presence In Japan
Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with Ina Research Co., Ltd. (hereinafter “INA”) to expand its business in Japan market.
As one of the world’s largest pharmaceutical markets, Japan has an established reputation for innovative drug research and development. The partnership will help introduce Biocytogen’s innovative animal models and its world-class antibody drug research capabilities to Japanese customers in various therapeutic fields including but not limited to immuno-oncology and auto-immune diseases. Under the agreement, INA represents Biocytogen as a sales agent and distributor to promote Biocytogen’s animal models and research services and capabilities in Japan.
“As both INA and Biocytogen having a strong focus on supporting pharmaceutical partner’s development on novel therapeutics, each has strength at different drug development stages. Therefore, the partnership would be a perfect match and create added value. By working as a team, we can provide a streamlined drug discovery and development platform to our business in Japan.” said Yuelei Shen, Ph.D., president and CEO of Biocytogen.
“We feel the thriving demand in Japan for animal models and non-clinical in vivo drug efficacy evaluation services, especially in the field of immunotherapy. Biocytogen‘s animal models and research capabilities have been recognized by world-wide customers including top MNCs in US, Europe and China for years and we would love to introduce them into Japan to support our customers and more importantly, to help accelerate drug innovation here in Japan.” said Kenshi Nakagawa, president and CEO of INA.
The partnership gives Biocytogen immediate access to INA’s well-established Japanese customer network including top pharmas, biotechs and institutes in the country. To fulfill the agreement, INA has already hosted a webinar in early October and will launch more events and campaigns to raise awareness of the models and services provided by its newly forged partner, Biocytogen.
About Beijing Biocytogen Co., Ltd.
Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to the patients around the world as its mission. Biocytogen has established a highly integrated antibody drug discovery platform based on a series of genetically-modified animal models. Biocytogen has developed the RenMabTM mouse model for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity.
Biocytogen has launched a pioneering antibody drug development plan (Project Integrum https://biocytogen.com/renmab-mouse/project-integrum/) to tackle difficult targets based on the immunization of RenMabTM knockout mice. Nearly 1,500 targets knockout mouse strains will be generated within 2 years for antibody discovery. Moreover, with the knockout immunization strategy, antibody hits cross-reacting with different species shall be more likely to be generated for better translational efficacy and toxicity evaluation.
With the world-class expertise in genetically-engineered animal development and maintenance with large-scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, the company provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application and has built its collaboration with more than 2,000 partners worldwide, including over 70% of top 20 MNCs.
About Ina Research Co., Ltd.
Founded in 1974, Ina Research’s headquarters is in the city of Ina, located in the Nagano prefecture, and it operates offices in Tokyo. The firm’s shares are traded publicly on the JASDAQ exchange.
Ina’s scientists primarily conduct analysis and safety and efficacy studies for customers in the pharmaceutical industry, though the organization also works with companies that produce agricultural chemicals and medical equipment.
Research specialties including drug dependence studies, efficacy studies for central nervous system therapies, cancer studies, reproductive and developmental toxicity studies, and animal models.
Ina has established a research center on Ina’s campus under the collaboration with academic institute to conduct non-clinical safety studies for CAR-T therapy, funded by the Japan Agency for Medical Research and Development.